Background. Amyotrophic lateral sclerosis (ALS) is a disease characterized by the progressive degeneration of the upper (UMN) and lower motor neurons (LMN), causing weakness, fatigue and muscular atrophy. Objective. To determine the prescription patterns of riluzole and the variables associated with its use in a population of patients with motor neuron disease. Methods. Descriptive cross-sectional study. Through a systematized database of approximately 3.5 million affiliates to the Health System of Colombia of Colombia, we selected patients who received riluzole. Sociodemographic and pharmacological variables and comorbidities were analyzed. Results. A total of 81 patients with motor neuron disease receiving riluzole were included, with an average age of 60.8±12.6 years; 48.1% were men. The prevalence of motor neuron disease was 2.29 per 100,000 people. Sixty-three percent received medications reflecting comorbidities or possible interactions with riluzole. The average cost per daily prescribed dose was USD 2.3. Conclusions. Riluzole was prescribed to patients with motor neuron disease in Colombia at the doses recommended and with a direct cost lower than that reported in other countries.